295 related articles for article (PubMed ID: 38183131)
1. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.
Dhoundiyal S; Srivastava S; Kumar S; Singh G; Ashique S; Pal R; Mishra N; Taghizadeh-Hesary F
Eur J Med Res; 2024 Jan; 29(1):26. PubMed ID: 38183131
[TBL] [Abstract][Full Text] [Related]
2. Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design.
Ataeinia B; Heidari P
PET Clin; 2021 Oct; 16(4):513-523. PubMed ID: 34364818
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumor theranostics.
Ichikawa Y; Kobayashi N; Takano S; Kato I; Endo K; Inoue T
Cancer Sci; 2022 Jun; 113(6):1930-1938. PubMed ID: 35271754
[TBL] [Abstract][Full Text] [Related]
5. Next generation radiotheranostics promoting precision medicine.
Pomykala KL; Hadaschik BA; Sartor O; Gillessen S; Sweeney CJ; Maughan T; Hofman MS; Herrmann K
Ann Oncol; 2023 Jun; 34(6):507-519. PubMed ID: 36924989
[TBL] [Abstract][Full Text] [Related]
6. Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.
Higuchi T; Chen X; Werner RA
Theranostics; 2024; 14(8):3178-3192. PubMed ID: 38855189
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles for SPECT and PET Imaging: Towards Personalized Medicine and Theranostics.
Polyak A; Ross TL
Curr Med Chem; 2018; 25(34):4328-4353. PubMed ID: 28875837
[TBL] [Abstract][Full Text] [Related]
8. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.
Grey N; Silosky M; Lieu CH; Chin BB
World J Gastroenterol; 2022 May; 28(17):1768-1780. PubMed ID: 35633909
[TBL] [Abstract][Full Text] [Related]
9. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
Burkett BJ; Bartlett DJ; McGarrah PW; Lewis AR; Johnson DR; Berberoğlu K; Pandey MK; Packard AT; Halfdanarson TR; Hruska CB; Johnson GB; Kendi AT
Radiol Imaging Cancer; 2023 Jul; 5(4):e220157. PubMed ID: 37477566
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography image-guided drug delivery: current status and future perspectives.
Chakravarty R; Hong H; Cai W
Mol Pharm; 2014 Nov; 11(11):3777-97. PubMed ID: 24865108
[TBL] [Abstract][Full Text] [Related]
11. New horizon of radiopharmaceuticals in management of neuroendocrine tumors.
Haq A; Rayamajhi S; Ponisio MR; Prasad V
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101797. PubMed ID: 37468403
[TBL] [Abstract][Full Text] [Related]
12. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
13. Theranostics of Metastatic Prostate Cancer Applying
Mirzaei S; Mohammed F; Zandieh S
Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
[TBL] [Abstract][Full Text] [Related]
14. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
Bolcaen J; Kleynhans J; Nair S; Verhoeven J; Goethals I; Sathekge M; Vandevoorde C; Ebenhan T
Theranostics; 2021; 11(16):7911-7947. PubMed ID: 34335972
[TBL] [Abstract][Full Text] [Related]
15.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
16. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
17. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
18. Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery.
Rijpkema M; Boerman OC; Oyen WJ
Curr Drug Targets; 2015; 16(6):625-33. PubMed ID: 25355181
[TBL] [Abstract][Full Text] [Related]
19. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
Choudhury P; Gupta M
Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
[TBL] [Abstract][Full Text] [Related]
20. [Oncological theranostics in nuclear medicine].
Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
